Not exact matches
The therapy is approved by the U.S. Food and Drug Administration for relapsed or treatment - resistant Hodgkin
lymphoma, and it is commonly prescribed to
patients whose disease has progressed after autologous stem cell transplant, a procedure that replenishes the bone marrow with the
patient's own healthy stem cells after therapy.
The FDA granted accelerated approval to nivolumab (Opdivo), an anti-PD-1 checkpoint inhibitor, for
patients with classical Hodgkin
lymphoma (cHL)
whose disease has relapsed or progressed after stem cell transplantation and the targeted antibody brentuximab vedotin (Adcetris).
The targeted drug brentuximab vedotin (Adcetris ®)-- a monoclonal antibody linked to a chemotherapy drug — is approved to treat Hodgkin
lymphoma in
patients whose disease has failed to respond to other treatment and, as of August 2015, to prevent relapse following a stem cell transplant.